ClinicalTrials.gg
RecruitingNCT03949881FEMJAUpdated Dec 16, 2025

Cultured Autologous Oral Mucosa Epithelial Sheet for the Treatment of Bilateral Limbal Stem Cell Deficiency

A Phase 1/2 interventional study of FEMJA transplatation in Total Bilateral Limbal Cell Deficiency, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by Hospices Civils de Lyon · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Some severe ocular burns or other rare ocular pathologies can be associated with a total loss of corneal epithelial stem cells (i.e. Limbal Stem Cell Deficiency - LSCD), which leads to cornea invasion by the conjunctiva and a subsequent opacification. When LSCD is total and bilateral, both eyes are affected leading to full blindness and a poor quality of life, with a paradoxical photophobia that may be painful. Fewer than 100 patients bear this rare condition in France.

When patients suffer from total and bilateral LSCD, no treatment has been proven to provide clinical benefits: contralateral limbus is unavailable for autologous limbus graft or autologous limbal stem cells culture; allogeneic limbus graft requires immunosuppressive treatment leading to too important serious adverse effects compared to the expected benefit, and does not last long (\< 2 years); and allogenic cornea transplantation is impossible since always rejected due to neovascularization.

A new way to treat these patients is to cultivate autologous corneal-like epithelium, and to graft it in order to restore transparency and to allow, if needed, a complementary corneal graft. Such an epithelium can be produced from autologous jugal mucosa cells. Epithelial jugal mucosa sheets transplantation has been assessed in a phase I/II clinical trial on 26 patients which showed that it is well-tolerated and effective but the culture technology used in this clinical trial is no longer available. A new enzymatic detachment process has been developed by the Hospices Civils de Lyon. Proof of concept was obtained from both in vitro and ex vivo studies: detachment with Collagenase at 0.5 mg/mL doesn't damage basement membrane proteins, so collagenase 0.5mg/mL-detached FEMJA were found to adhere, continue to ensure renewal of the differentiated epithelium 15 days after grafting onto an ex vivo porcine de-epitheliazed stroma model.

Considering these results, we aim to perform a clinical trial in order to evaluate tolerance and efficacy of the autologous jugal mucosa cell sheet (Feuillets Epithéliaux de Muqueuse Jugale Autologue - FEMJA) cultured with this innovative process.

02

Conditions studied

  • Total Bilateral Limbal Cell Deficiency

Keywords

  • FEMJA transplantation
  • Epithelial jugal mucosa sheet
  • Limbal Stem-Cell Deficiency
03

In context

Limbal Stem Cell Deficiency

38 studies on the registry are indexed under Limbal Stem Cell Deficiency; 15 are open to participants now.

This study's planned enrollment of 40 is above the median of 20 across 23 interventional studies indexed under Limbal Stem Cell Deficiency.

Browse Limbal Stem Cell Deficiency studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged ≥ 18 years
  • Signed and dated for participation in the study
  • Total bilateral limbal stem-cell deficiency
  • Caused by thermal or chemical burn, cornea transplantation, and other bilateral disorders of the ocular surface
  • Severe loss of vision (\<2/10 on decimal scale or/and EDTRS)
  • The subject must be covered by a social security system

Exclusion criteria

Exclusion Criteria

  • Eye inflammation
  • Strictly unilateral ocular affliction
  • Acute systemic infection, objectified during consultation by the investigator and on the following paraclinical parameter: C Reactive Protein rate
  • History of acute phase of ocular inflammation in the previous year
  • History of neoplasic disease
  • Glaucoma defined as intra ocular pressure (air tonometer and applanation tonometer) ≥ 22mmHg
  • Total symblepharon (comprising eyelid aperture): impossibility to open the 2 eyes
  • History of hyper sensibility or allergy to antibiotics or serum
  • Women who are or may be pregnant or breastfeading
  • Patients with any active infectious disease (, , , HTLV-1 and syphilis)
  • Patients who are otherwise ineligible for participation in the study in the opinion of the investigator.
  • Delay of less than one year after chemical or thermal burns
  • Person under judicial protection
  • related to anesthesia
  • Contraindication to fluoresceine
  • Oral mucosa tumor, pharynx or larynx tumor
  • Fungal or viral infection of the ENT area
  • Bacteria infection of the oral mucosa, pharynx or larynx.
  • to ofloxacin (or other quinolone drugs), fluorometholone or betamethasone.
  • Hypersensitivity to one of the of the eye drops used: Monosodium phosphate, anhydrous disodium phosphate, polysorbate 80, sodium chloride, sodium edetate, polyvinyl alcohol, benzalkonium chloride, hydroxypropylmethylcellulose, hydrochloric acid, sodium hydroxide, lactose, cellulose, crospovidone, aspartam, magnesium stearate,
  • Phenylketonuria
  • Psychotic states not yet controlled by treatment;
  • Vaccination with a
  • Bacterial, fungal, myco-bacterial infection of eye structures.
  • Some evolving viral infections (including hepatitis, herpes, chickenpox, shingles) or other viral infections of the cornea or conjunctiva (except for a keratitis to Herpes zoster).
  • Patients treated with Class IA or III antiarrhythmics, tricyclic antidepressants, macrolides and antipsychotics
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    FEMJA transplatation

    FEMJA epithelium is obtained by culturing oral mucosal epithelial cells without any need of support substrates, or carriers, and the transparent fabricated sheets show strong, rapid adhesion on corneal stroma in vivo, without any need for suturing. The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma. The sheet is grafted without suture onto the exposed stromal bed after removal of the conjunctiva and fibrosis from the cornea. The grafted corneal surface is then covered with a soft permanent contact lens for protection during healing (between 3 to 15 days, according to tolerance) If the stroma appears opaque because of deep stromal scars a corneal allograft will be performed 12 months after FEMJA transplantation.

    Biological: FEMJA transplatation

Interventions

  • BiologicalFEMJA transplatation

    The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma. The sheet is grafted without suture onto the exposed stromal bed after removal of the conjunctiva and fibrosis from the cornea. The grafted corneal surface is then covered with a soft permanent contact lens for protection during healing (between 3 to 15 days, according to tolerance) If the stroma appears opaque because of deep stromal scars a corneal allograft will be performed 12 months after FEMJA transplantation.

    Also known as: Cultivated oral mucosal epithelium transplantation

06

What researchers measure

Primary outcomes

  1. Number of patients with any improvement in visual acuity

    Visual acuity measured at baseline (preoperative status) and 24 months after a jugal mucosa epithelial cell sheet transplantation (FEMJA transplantation), according to the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. ETDRS LogMAR tests allow measurement of very low visual acuity.

    Time frame: 24 months after FEMJA transplantation

Secondary outcomes

  1. Number of successful FEMJA transplantations

    A success is defined by obtaining at least one FEMJA sheet that could be grafted without perforating it

    Time frame: During 1 day of transplantation

  2. Number of adverse events related to the procedure

    Adverse events related to the procedure; especially expected adverse events: inflammation, infection, and perforation.

    Time frame: Up to 24 months after FEMJA transplantation

  3. Improvement in physical signs

    Any improvement from inclusion in physical signs measured with a slit lamp, in terms of: persistant epithelial defect; superficial punctate epithelial keratitis; and conjunctival epithelium on cornea.

    Time frame: 6 months, 12 months, 18 months and 24 months after FEMJA transplantation

  4. Improvement in neovascularization

    Number of patients with a decrease in the number of vascular pediculus near the limbus and their activity, compared to inclusion.

    Time frame: 6 months, 12 months, 18 months and 24 months after FEMJA transplantation

  5. Improvement in symptoms, i.e. functional signs

    Number of patients with an improvement in functional signs measured with Likert scales by self-reporting from the patient, in terms of: photophobia, eye dryness, and pain, compared to inclusion.

    Time frame: 6 months, 12 months, 18 months and 24 months after FEMJA transplantation

  6. Corneal graft rejection

    Among patients with secondary corneal graft, number of patients with graft rejection defined by intraocular pression (≥ 22mmHg) and significant increase in the thickness of the stroma of the cornea compared to the measured value just post graft on corneal topography.

    Time frame: 24 months after FEMJA transplantation

  7. Correlation between biological FEMJA characteristics and changes in visual acuity

    FEMJA characteristics (extraction yield, percentage of proliferative epithelial cells) will be compared according to the clinical response for changes in visual acuity.

    Time frame: 24 months after FEMJA transplantation

07

Study locations

1 of 1 sites recruiting
  • Ophthalmology department, Edouard Herriot hospital, Hospices Civils de Lyon
    Lyon, 69003, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2020 (actual). Primary completion is estimated for May 2031, 126 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2019
First posted
May 14, 2019
StartActual
Nov 13, 2020
Primary completionEst.
May 13, 2031
CompletionEst.
May 13, 2031
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03949881
Responsible party
Sponsor
First posted
May 14, 2019
Start date
Nov 13, 2020
Primary completion
May 13, 2031 (estimated)
Completion
May 13, 2031 (estimated)
Last update
Dec 16, 2025

Study contacts

Carole BURILLON, MD
Contact
carole.burillon@chu-lyon.fr
472.11.62.17 ext. +33
Celine AUXENFANS
Contact
celine.auxenfans@chu-lyon.fr
472 11 04 65 ext. +33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion